FBXO4 Inhibitors

FBXO4 Inhibitors encompasses compounds that potentially modulate the activity of FBXO4, an F-box protein involved in the ubiquitin-proteasome degradation pathway. These inhibitors do not directly target FBXO4 but instead impact the cellular processes and pathways in which FBXO4 operates. Compounds like MG132, Bortezomib, Lactacystin, Carfilzomib, Velcade, Oprozomib, Marizomib, IXazomib, and Delanzomib are primarily proteasome inhibitors. They exert their influence by disrupting the proteasomal degradation mechanism, a pathway critical for the function of FBXO4 in tagging proteins for degradation. By inhibiting the proteasome, these compounds can alter the balance of protein degradation and synthesis, potentially impacting the regulatory roles of FBXO4. In addition, PYR-41 and MLN4924 target the ubiquitination process itself. PYR-41 inhibits the ubiquitin-activating enzyme E1, a crucial step in the ubiquitination cascade, while MLN4924 inhibits the NEDD8-activating enzyme, disrupting neddylation - a process related to ubiquitination. Both these actions can indirectly affect FBXO4's role in tagging proteins for ubiquitination. Furthermore, Auranofin, by inhibiting thioredoxin reductase, can influence oxidative stress pathways. This indirect approach might affect FBXO4's function, as oxidative stress is known to play a role in protein degradation pathways.